EUCTR2007-005933-12-IT进行中（未招募）1 期
Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology - ND
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 104
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must have histologically or cytologically confirmed diagnosis of MTC or DTC. Measurable disease meeting the following criteria (revised per Amendment 01): o at least one lesion (≥1.5 cm in longest diameter for non-lymph nodes and ≥2.0 cm in longest diameter for lymph nodes) which is serially and accurately measurable according to Modified RECIST using either CT/MRI o Lesions that have had external beam radiotherapy (EBRT) must show evidence of progressive disease based on Modified RECIST to be deemed a target lesion Patients must show evidence of disease progression by RECIST using site assessment of CT/MRI scans within 12 months (+ 1 month to allow for variances in patients scanning intervals) prior to study entry (revised per Amendment 01). Patients with DTC must be 131I refractory/resistant defined by at least one of the following: a. One or more measurable lesions that have never demonstrated 131I uptake on any radioiodine scan based on either collected scans or reports, b. One or more measurable lesions with disease progression by RECIST within 12 months (+1 month to allow for variances in patient scanning intervals) of 131I therapy despite 131I uptake on radioiodine scan based on site assessment of CT/MRI scans (revised per Amendment 01). c. Cumulative activity of 131I of >600 mCi or 22 gigabequerel (GBq), with the last dose administered at least 6 months prior to study entry.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Anaplastic thyroid carcinoma, thyroid lymphoma, mesenchymal tumors of the thyroid, metastases to the thyroid Significant cardiovascular impairment (history of congestive heart failure > NYHA Class II, unstable angina or myocardial infarction within 6 months of study start, or serious cardiac arrhythmia) Active hemoptysis (bright red blood of at least ? teaspoon) in the 28 days prior to study entry
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Trial of an experimental drug E7080 to establish how E7080 works in treating patients with Medullary Thyroid Cancer (MTC) and Differentiated Thyroid Cancer (DTC) that is refractory/resistant to Iodine-131 treatment and unresectable (the cancer cannot be removed). The Trial is taking place worldwide. Both patients and their treating Doctors know that patients are receiving active drug.EUCTR2007-005933-12-GBEisai Limited104
进行中（未招募）
1 期
Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology.Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK/PD) relationships of E7080. Note: *= to the power.MedDRA version: 9.1 Level: LLT Classification code 10065252 Term: Solid tumorEUCTR2007-005933-12-FREisai Limited100
进行中（未招募）
1 期
A Phase 2 Trial of an experimental drug E7080 to establish how E7080 works in treating patients with Medullary Thyroid Cancer (MTC) and Differentiated Thyroid Cancer (DTC) that is refractory/resistant to Iodine-131 treatment and unresectable (the cancer cannot be removed). The Trial is taking place worldwide. Both patients and their treating Doctors know that patients are receiving active drug.Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]:Note: *= to the power.MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.1Level: PTClassification code 10016935Term: Follicular thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033701Term: Papillary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-005933-12-PLEisai Limited104
进行中（未招募）
2 期
Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by HistologyCancer - ThyroidThyroid CancerACTRN12609000002280Eisai Inc100
进行中（未招募）
1 期
Therapy of Angiosarcomas with standard therapy paclitaxel in combination with pazopanib (Votrient)Advanced and relapsed angiosarcomaMedDRA version: 18.1Level: LLTClassification code 10002481Term: Angiosarcoma stage unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10072814Term: Breast angiosarcoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10072813Term: Breast angiosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10025223Term: LymphangiosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: HLTClassification code 10025224Term: LymphangiosarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10057700Term: Angiosarcoma non-metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10002480Term: Angiosarcoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10018827Term: HaemangiosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10072891Term: Skin angiosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10067388Term: Hepatic angiosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTCEUCTR2012-005846-39-DEniversity of Heidelberg44